Hippokratia 2016, 20(3):198-203
Inci A1, Olmaz R1, Sarı F2, Coban M1, Ellidag HY3, Sarıkaya M1
1Division of Nephrology, Internal Medicine, Antalya Training and Research Hospital, 2Division of Nephrology, Internal Medicine, Akdeniz University, Faculty of Medicine, 3Division of Biochemistry, Internal Medicine, Antalya Training and Research Hospital, Antalya, Turkey
Background: In the present study, we aimed to assess the relationship between the levels of soluble Klotho (s-Klotho) and oxidative stress markers in diabetic nephropathy patients with different stages of chronic kidney disease (CKD) and albuminuria levels.
Methods: We enrolled 109 patients with type 2 diabetes (mean age, 61.63 ± 9.77 years) and 32 healthy controls (mean age, 49.53 ± 7.32 years) between January and June 2014. Patients were classified into three groups based on their urinary albumin/creatinine ratio (UACR). Blood samples were collected to measure the levels of s-Klotho, serum creatinine, calcium, phosphorus, 25-hydroxyvitamin D3, and parathyroid hormone (PTH). We used the total oxidant status (TOS), total antioxidant status (TAS), ischemia-modified albumin (IMA), and ischemia-modified albumin ratio (IMAR) values to measure the oxidative status. Moreover, the oxidative stress index (OSI) was estimated as the percentage ratio of TOS/TAS values.
Results: The TOS, TAS, and OSI values were significantly greater in the diabetic nephropathy patients compared to controls (p <0.001). When patients were classified based on their UACR, we noted that the TOS, OSI, and IMA values did not significantly differ, although the TAS (p <0.001), and IMAR (p =0.002) values significantly differed between the groups. The s-Klotho levels also significantly differed (p =0.031) between the groups. These s-Klotho levels exhibited a significant positive correlation with TOS (r =0.186, p =0.034) and OSI (r =0.207 p =0.018), but showed no correlation with the estimated glomerular filtration rate; UACR; HbA1c, calcium, phosphorus, and PTH levels; and TAS, IMA, and IMAR values.
Conclusion: Oxidative stress is greater in patients with diabetic nephropathy, and the TOS was positively correlated with s-Klotho levels in diabetic patients. The therapeutic reduction of oxidative stress in patients with diabetic nephropathy could improve the renal and cardiovascular outcomes. Hippokratia 2016, 20(3): 198-203.
Key words: Diabetes, diabetic nephropathy, oxidative stress, s-Klotho, soluble Klotho
Corresponding author: Inci Ayca, Division of Nephrology, Internal Medicine, Antalya Training and Research Hospital, Antalya, Turkey, tel: +905053557358, fax: +902422494400, e-mail: firstname.lastname@example.org
Diabetes is the most common cause of chronic kidney disease (CKD) and is associated with an increased risk for cardiovascular morbidity and mortality1. However, the underlying pathogenic mechanism linking diabetic nephropathy with cardiovascular disease (CVD) remains unclear. In addition to traditional risk factors such as hypertension, hyperglycemia, and dyslipidemia, inflammation/oxidative stress and endothelial dysfunction may also contribute to the pathogenesis of atherosclerosis and increased cardiovascular risk among these patients2.
Klotho is an aging suppressor gene that was first discovered as a membrane protein. Membrane Klotho forms a complex with the fibroblast growth factor 23 (FGF23) receptor and serves as a mediator for the actions of FGF23, including urinary phosphate (P) excretion, inhibition of calcitriol [1,25(OH)2D] secretion, and inhibition of parathyroid hormone (PTH) synthesis and secretion3-5. Klotho may also be released into circulation via ectodomain shedding, after which it transforms into soluble Klotho (s-Klotho) and functions as a humoral factor. s-Klotho is involved in the regulation of nitric oxide production in the endothelium, preservation of endothelial integrity and permeability, calcium (Ca) homeostasis in the kidneys, and the inhibition of intracellular insulin and insulin-like growth factor-1 signalling6.
Oxidative stress is defined as a disturbance in the balance between the production of reactive oxygen species (ROS) and antioxidants. Certain clinical and laboratory markers can be used to detect the oxidative stress and antioxidant status. In particular, the measurement of total antioxidant status (TAS) and total oxidant status (TOS) can provide useful information on the overall serum antioxidative status of an individual7. Albumin is a major determinant of the antioxidant capacity of human serum. The molecule has the ability to bind and carry radical scavengers, and sequesters transition metal ions with pro-oxidant activity, in addition to its direct antioxidant capabilities. The generation of ROS and free radicals can transiently modify the N-terminal region of albumin and produce an increase in the concentration of ischemia-modified albumin (IMA). Some previous studies have described IMA as a marker of ischemia and oxidative stress8,9. A defect in Klotho gene expression can lead to premature aging. In fact, Yamamoto et al showed that the Klotho-induced inhibition of insulin/insulin-like growth factor 1 signaling is associated with an increased resistance to oxidative stress, which may potentially contribute to the anti-aging properties of Klotho10. Recently, we investigated the s-Klotho and FGF23 levels in diabetic nephropathy with different stages of albuminuria in the same study population, and we intended to investigate the factors affecting the levels of s-Klotho11. In the present study, we investigated the relationship between the levels of s-Klotho and oxidative stress markers in diabetic nephropathy patients with different stages of CKD and albuminuria levels.
Between January and June 2014, we enrolled 109 patients with diabetic nephropathy (mean age: 61.63 ± 9.77 years) and 32 healthy controls (mean age: 49.53 ± 7.32 years). Patients were recruited at the outpatient clinic of the Nephrology Unit of Antalya Research and Training Hospital while healthy controls from the hospital staff. The healthy group had no chronic illness or drug use, and the age did not match with that of the diabetic group. We excluded from the study patients aged <18 years, pregnant women, those with hepatic diseases, other kidney diseases, clinically apparent infections, or active malignancy, and those using vitamin D or phosphate binders to eliminate possible conditions that influence oxidative stress parameters and s-Klotho levels. We conducted this study according to the Declaration of Helsinki and the guidelines of Good Clinical Practice and it was approved by the Ethics Committee of Antalya Training and Research Hospital (No: 215/01.01.2014). All the patients and healthy controls provided written informed consent.
Patients were classified into three groups based on their urinary albumin/creatinine ratio (UACR): the normoalbuminuria group (UACR <30 mg/g), microalbuminuria group (UACR =30-300 mg/g), and macroalbuminuria group (UACR >300 mg/g). The CKD epidemiology collaboration (CKD-EPI) equation for the glomerular filtration rate was used to calculate the estimated glomerular filtration rate (eGFR).
Blood and urine samples were collected in the morning after an 8h fast. The serum was stored at −80°C. Blood was analyzed for fibroblast growth factor 23 (FGF23), s-Klotho, PTH, P, Ca, creatinine, and 25-hydroxyvitamin D3 levels. The urinary protein-to-creatinine ratio (UPCR) and UACR were calculated via spot urine protein, albumin, and creatinine measurements.
The serum s-Klotho levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (YH Biosearch, Shanghai, China), with a coefficient of variation of <10 % for both parameters; the detection range of serum soluble α-Klotho level assay ranged from 0.05 to 20 ng/mL. These assays used the quantitative sandwich enzyme immunoassay technique. To avoid variability within each assay, measurements were performed simultaneously, in duplicate, using the same ELISA kit.
We used the TOS, TAS, IMA, and IMA/serum albumin ratio (IMAR) values to measure the oxidative status. The serum TAS was measured using an automated colorimetric measurement method developed by Erel7 and a commercially available reagent kit (Relassay®, Turkey). In this method, antioxidants in the sample reduce the dark blue-green-coloured 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) radical to the colorless reduced ABTS form. The change in absorbance at 660 nm is related to the total antioxidant level in the sample. The results are expressed as micromolar trolox equivalent per liter.
The TOS of the plasma was measured using an automated colorimetric measurement method developed by Erel12 and a commercially available reagent kit (Relassay®, Turkey). In this method, the oxidants present in the sample oxidize the ferrous ion chelator complex to ferric ion, which produces a colored complex with a chromogen in an acidic medium. The results are expressed in terms of micromolar hydrogen peroxide equivalent per liter (μmol H2O2 Equiv/L).
The percentage ratio of the TOS to TAS level yields the oxidative stress index (OSI). For calculation, the resulting micromolar unit of TAS is changed to millimoles per liter, and the OSI value is calculated using the following formula: OSI (arbitrary unit) = TOS (micromolar hydrogen peroxide equivalent per liter)/TAS (micromolar trolox equivalent per liter).
The IMA level (reflecting the reduced cobalt–albumin-binding capacity) was measured using the rapid and colorimetric method developed by Bar-Or et al8. In brief, 200 μl of patients’ serum was transferred into glass tubes and 50 μl of 0.1 % CoCl2*6H2O (lot S38901-248, Sigma-Aldrich, St Louis, MO, USA) was added. After gentle shaking, the mixture was incubated for 10 min to ensure sufficient cobalt-albumin binding. Thereafter, 50 μl of 1.5 mg/ml dithiothreitol (DTT) (lot D5545-1G, Sigma-Aldrich) was added as a coloring agent. After 2 min, we added 1 ml of 0.9 % NaCl to stop the binding between cobalt and albumin. For every specimen a blank was prepared; at the DTT addition step, we used 50 μl of distilled water instead of 50 μl of 1.5 mg/ml DTT to obtain a blank without DTT. The absorbance values were recorded at 470 nm using a spectrophotometer (UV1201, Shimadzu, Kyoto, Japan). The color formation in specimens with DTT was compared to color formation in the blank tubes, and the results are expressed as absorbance units. The IMAR was also estimated and was used to eliminate the effect of reduced albumin concentrations.
Continuous variables are presented as means ± standard deviation and categorical variables are presented as percentages. The Kolmogorov-Smirnov test was used to verify the normality of the distributions of continuous variables. Statistical analysis of the clinical data between the two groups was performed using unpaired t-tests for parametric data and the Mann-Whitney U test for nonparametric data. Moreover, one-way analysis of variance (ANOVA) or the Kruskal- Wallis test was used to evaluate comparisons between ≥3 groups. Bonferroni correction was applied to posthoc analyses. Correlations were assessed with Pearson or Spearman correlation coefficients, whereas the chi-square test was used for categorical variables. The factors related to the serum soluble α-Klotho levels in patients were evaluated using multiple linear regression analysis. The analyses were performed with PASW 18 software (SPSS/IBM, Chicago, IL, USA), and two-tailed p values of <0.05 were considered statistically significant.
The clinical and demographic characteristics of the patients with diabetic nephropathy (n =109) and the controls (n =32) are shown in Table 1. The levels of creatinine, s-Klotho, and PTH were significantly greater, whereas the eGFR was significantly lower in the patient group compared to the healthy controls (p <0.001). The TOS, TAS, and OSI values were also significantly greater in the patient group (p <0.001). However, the IMA and IMAR values did not differ significantly between the groups (Table 1).
UACR values were obtained from 107 patients, who were then assigned into three groups based on their UACR; accordingly, 28, 29, and 50 patients were included in the normoalbuminuria, microalbuminuria, and macroalbuminuria groups, respectively. Table 2 presents the main parameters of the patients in these groups. One-way ANOVA indicated significant differences between these groups in terms of the creatinine (p <0.001), PTH (p =0.002), Ca (p =0.002), glycated haemoglobin (HbA1c) (p <0.001), and albumin levels (p <0.001). Moreover, the s-Klotho levels were also significantly different between the groups (p =0.031). The TOS, OSI, and IMA values did not significantly differ between the groups, although the TAS (p <0.001) and IMAR (p =0.002) values were significantly different.
Correlation analyses were performed between s-Klotho levels and age, UACR, other bone mineral metabolism parameters, and oxidative stress marker levels (Table 3). A significantly positive correlation was observed between the s-Klotho levels and TOS (r =0.186, p =0.034) and OSI (r =0.207, p =0.018). However, no significant correlation was found between the s-Klotho levels and eGFR; UACR; HbA1c, Ca, P, and PTH levels; and TAS, IMA, and IMAR values.
Regression analysis was performed to determine the effect of age; UACR; Ca, P, and PTH levels; eGFR; and TOS, TAS, OSI, IMA, and IMAR values on the s-Klotho levels in patients with CKD. A significant relationship was only observed between the serum s-Klotho levels and the TOS (β =0.187, p =0.034) and IMAR (β = -0.230, p =0.014) values (Table 4).
CVD, rather than progression to end-stage renal disease, is the leading cause of death in CKD patients. Moreover, oxidative stress is a non-traditional risk factor of CVD. Oxidative stress induces endothelial dysfunction and atherosclerosis progression by reducing nitric oxide availability. In fact, oxidative stress and changes in cellular function play a key role in the development and progression of diabetic nephropathy13. Previous studies indicated an increase in ROS generation in diabetic patients, which is a major contributor to the pathogenesis of diabetic nephropathy14,15. Nitric oxide production and nitric oxide synthase isoform expression in the kidney are upregulated during the early phase of diabetic nephropathy; as the renal function declines, the nitric oxide levels decrease16. In experimental studies, renal nitric oxide levels decreased due to increased oxidative stress, primarily as a result of the enhanced expression of superoxide dismutase (SOD) and catalase17. In fact, superoxide radicals play an important role in diabetic complications by causing vascular dysfunction; these radicals are primarily cleared by copper/zinc superoxide dismutase. Moreover, extracellular SOD levels are higher in patients with diabetes, possibly as a compensatory effect that reflects the presence of increased oxidative stress and vascular injury. Liu et al observed an increase in extracellular SOD levels in diabetic patients and found that SOD levels were positively correlated with s-Klotho levels in diabetic patients18. In the present study, we observed elevated TOS, TAS, and OSI values in patients with diabetic nephropathy, as compared to those in healthy controls, consistent with the current literature. We also used IMA as a marker of oxidative stress. A 1 g/dl change in albumin has been found to produce a contrasting change of 2.6 % in the IMA levels, thus exhibiting a negative correlation. To avoid the impact of the differences in albumin concentration between the groups, we evaluated the IMA values along with those of albumin, and the formula ‘IMA value/individual serum albumin concentration’ was used to maintain the IMAR.
In diabetic patients, microalbuminuria is the first predictive marker that shows the presence of extensive endothelial damage and progression to macrovascular disease. Ukinc et al showed that elevated IMA levels may indicate an underlying subclinical vascular disease in type 2 diabetes mellitus patients; in their study, the IMA levels in type 2 diabetic patients with microalbuminuria were markedly higher as compared to those in normoalbuminuric diabetic individuals19. In another study in diabetic nephropathy patients, the IMA levels progressively increased with the degree of albuminuria20. In the present study, the IMA and IMAR values did not differ significantly between diabetic nephropathy patients and healthy controls; however, when the patients were divided based on their UACR values, the IMAR value was found to be significantly different among the groups. As the renal disease progressed, the IMAR values increased.
Klotho is expressed in multiple tissues, with particularly high levels in the kidney. In CKD, Klotho tissue expression begins to decrease during the early stages of the disease21. In the present study, patients with CKD secondary to diabetic nephropathy exhibited higher s-Klotho levels as compared to healthy controls. As we mentioned before in the same study population, we investigated the s-Klotho and FGF23 levels in patients with Stage 1–4 diabetic nephropathy with different stages of albuminuria, and found an increase in the s-Klotho levels, in comparison with the control group; however, there was no significant correlation between the s-Klotho levels and eGFR11. Consistent with these findings, the serum levels of s-Klotho were not associated with kidney function in patients with CKD Stages 2, 3a, and 4 in another cohort study22. Lee et al23 also described increased s-Klotho levels in patients with diabetes, although the kidney function was normal in those patients.
When patients were grouped according to their UACR values, we found that the s-Klotho levels were greatest in those with normoalbuminuria and decreased as albumin excretion increased, despite the reduction in eGFR. As we mentioned before, nitric oxide production is upregulated during the early phase of diabetic nephropathy. We believed that s-Klotho production is also similarly upregulated during the early stages of diabetic nephropathy. In the present study, an increase in s-Klotho levels was associated with an increase in the TOS and OSI values, as s-Klotho has anti-inflammatory functions in the kidney, in addition to its ability to increase resistance to oxidative stress. However, with the decline in renal function, the renal s-Klotho expression also decreased, which was followed by a reduction in plasma s-Klotho levels. In a previous study, Adema et al assessed the effect of anti-oxidative therapy on α-Klotho concentrations in patients with mild-moderate CKD, and found that the s-Klotho concentrations did not differ in the treatment group24. In addition, Antoniadi et al showed that SOD levels did not significantly differ between hemodialysis patients and healthy volunteers, and these findings indicate a lack of adaptation to increased oxidative stress, which a common characteristic among patients on dialysis25. Prior to the decline in renal function among patients with normoalbuminuria or microalbuminuria, antioxidant therapy may be useful. Moreover, the expression of the Klotho gene reduces following the activation of the renin angiotensin aldosterone (RAS) system26. The RAS blockade with the angiotensin-converting enzyme inhibitor or angiotensin receptor blocker may upregulate the s-Klotho levels. However, in the present study, we did not assess the effect of these drugs on the levels of oxidative stress markers and s-Klotho.
The present study has certain limitations. Due to its cross-sectional nature, the cause and effect relationship cannot be easily established. Moreover, the diabetic and control group were not matched in terms of age and this may have affected our results. Also, additional plasma markers of oxidative stress should be assessed in further studies. In fact, a future study with a larger sample size would be able to clarify the relationship between s-Klotho levels, oxidative stress, and albuminuria in diabetic nephropathy patients.
In conclusion, oxidative stress is greater in patients with diabetic nephropathy, and we found that oxidative status is an important factor affecting s-Klotho levels. Moreover, the therapeutic reduction of oxidative stress during the early stages of diabetic nephropathy can improve the renal and cardiovascular outcomes in these patients.
Conflict of interest
The authors declare no conflict of interest.
1. Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, et al. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis. 2010; 55: S1-S420.
2. Roberts AC, Porter KE. Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diabetes Vasc Dis Res. 2013; 10: 472-482.
3. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390: 45-51.
4. Wang Y, Sun Z. Current understanding of klotho. Ageing Res Rev. 2009; 8: 43-51.
5. Komaba H, Fukagawa M. The role of FGF23 in CKD–with or without Klotho. Nat Rev Nephrol. 2012; 8: 484-490.
6. Kitagawa M, Sugiyama H, Morinaga H, Inoue T, Takiue K, Ogawa A, et al. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS One. 2013; 8: e56695.
7. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004; 37: 277-285.
8. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischaemia-a preliminary report. Emerg Med J. 2000; 19: 311-315.
9. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart. 2006; 92: 113-114.
10. Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H, et al. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem. 2005; 280: 38029-38034.
11. Inci A, Sari F, Coban M, Olmaz R, Dolu S, Sarıkaya M, et al. Soluble Klotho and fibroblast growth factor 23 levels in diabetic nephropathy with different stages of albuminuria. J Investig Med. 2016; 64: 1128-1133.
12. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005; 38: 1103-1111.
13. Modaresi A, Nafar M, Sahraei Z. Oxidative stress in chronic kidney disease. Iran J Kidney Dis. 2015; 9: 165-179.
14. Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev. 2001; 17: 189-212.
15. Davì G, Falco A, Patrono C. Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal. 2005; 7: 256-268.
16. Mumtaz FH, Dashwood MR, Khan MA, Thompson CS, Mikhailidis DP, Morgan RJ. Down-regulation of nitric oxide synthase in the diabetic rabbit kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Curr Med Res Opin. 2004; 20: 1-6.
17. Prabhakar S, Starnes J, Shi S, Lonis B, Tran RJ. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. Am Soc Nephrol. 2007; 18: 2945-2952.
18. Liu JJ, Liu S, Morgenthaler NG, Wong MD, Tavintharan S, Sum CF, et al. Association of plasma soluble α-klotho with pro-endothelin-1 in patients with type 2 diabetes. Atherosclerosis. 2014; 233: 415-418.
19. Ukinc K, Eminagaoglu S, Ersoz HO, Erem C, Karahan C, Hacihasanoglu AB, et al. A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocrine. 2009; 36: 425-432.
20. Ahmad A, Manjrekar P, Yadav C, Agarwal A, Srikantiah RM, Hegde A. Evaluation of Ischemia-Modified Albumin, Malondialdehyde, and Advanced Oxidative Protein Products as Markers of Vascular Injury in Diabetic Nephropathy. Biomark Insights. 2016; 11: 63-68.
21. Kalaitzidis RG, Duni A, Siamopoulos KC. Klotho, the Holy Grail of the kidney: from salt sensitivity to chronic kidney disease. Int Urol Nephrol. 2016; 48: 1657-1666.
22. Seiler S, Wen M, Roth HJ, Fehrenz M, Flügge F, Herath E, et al. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int. 2013; 83: 121-128.
23. Lee EY, Kim SS, Lee JS, Kim IJ, Song SH, Cha SK, et al. Soluble α-klotho as a novel biomarker in the early stage of nephropathy in patients with type 2 diabetes. PLoS One. 2014; 9: e102984.
24. Adema AY, van Ittersum FJ, Hoenderop JG, de Borst MH, Nanayakkara PW, Ter Wee PM, et al; NIGRAM consortium. Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating α-Klotho Concentrations. PLoS One. 2016; 11: e0144121.
25. Antoniadi G, Eleftheriadis T, Liakopoulos V, Kakasi E, Kartsios C, Passadakis P, et al. Effect of one-year oral alpha-tocopherol administration on the antioxidant defense system in hemodialysis patients. Ther Apher Dial. 2008; 12: 237-242.
26. de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol. 2011; 22: 1603-1609.